Blog

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju/mdanderson.org

Apr 29, 2025, 09:33

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article by Naval Daver, et al. on X:

“Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by Naval Daver and Hussein Abbas.”

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.

Journal: Clinical Cancer Research.

Authors: Naval Daver, et al.

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

More posts featuring Naveen Pemmaraju.

AML azacitidine BPDCN Program cancer fight against cancer Global fight against cancer Hussein Abbas magrolimab MD Anderson Cancer Center Naval Daver Naveen Pemmaraju OncoDaily Oncology University of Texas venetoclax

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action